Brief: Inflarx Assessing Feasibility Of Broadened Strategy For Anca‑Associated Vasculitis In Europe Following EMA Recommendation On Tavneos
30/06/2026 13:49
BRIEF-Inflarx Assessing Feasibility Of Broadened Strategy For Anca‑Associated Vasculitis In Europe Following EMA Recommendation On Tavneos June 30 (Reuters) - InflaRx NV IF0G.F:
INFLARX ASSESSING FEASIBILITY OF BROADENED STRATEGY FOR ANCA‑ASSOCIATED VASCULITIS IN EUROPE FOLLOWING EMA RECOMMENDATION ON TAVNEOS
INFLARX NV - TO ENGAGE WITH EMA ON VILOBELIMAB AND IZICOPAN FOR AAV APPROVAL
Source text: ID:nGNX27tcbm
Further company coverage: IF0G.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx Assessing Feasibility Of Broadened Strategy For Anca‑Associated Vasculitis In Europe Following EMA Recommendation On Tavneos
Brief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction